{"id":383623,"date":"2010-03-03T09:34:46","date_gmt":"2010-03-03T14:34:46","guid":{"rendered":"http:\/\/www.xconomy.com\/?p=66305"},"modified":"2010-03-03T09:34:46","modified_gmt":"2010-03-03T14:34:46","slug":"seattle-genetics-gets-roche-cash","status":"publish","type":"post","link":"https:\/\/mereja.media\/index\/383623","title":{"rendered":"Seattle Genetics Gets Roche Cash"},"content":{"rendered":"\n<div style=\"text-transform:uppercase\"><a href=\"http:\/\/www.xconomy.com\/tag\/Biotech\/\">Biotech<\/a>, <a href=\"http:\/\/www.xconomy.com\/tag\/deals\/\">deals<\/a>, <a href=\"http:\/\/www.xconomy.com\/tag\/cancer\/\">cancer<\/a><\/div>\n<p>\t\t<strong>Luke Timmerman wrote:<\/strong><\/p>\n<p>Seattle Genetics <a href=\"http:\/\/investor.seagen.com\/phoenix.zhtml?c=124860&amp;p=irol-newsArticle&amp;ID=1398149&amp;highlight=\">said today<\/a> it has received an undisclosed milestone payment from Genentech, a wholly owned unit of Switzerland-based Roche. Seattle Genetics (NASDAQ: <a href=\"http:\/\/finance.yahoo.com\/q?s=SGEN\">SGEN<\/a>) is getting the payment because Genentech has filed an application with the FDA to begin clinical trials of an antibody for cancer that uses Seattle Genetics&#8217; technology that links those targeting agents to toxins that make them more potent. Seattle Genetics has now received $110 million in total payments from partners who use the antibody-linking technology, and it stands to receive more in royalties if they ever become marketed products.<\/p>\n<div class=\"postFooter\"><a href=\"http:\/\/www.xconomy.com\/seattle\/2010\/03\/03\/seattle-genetics-gets-roche-cash\/#comments\">Comments<\/a> | <a href=http:\/\/www.xconomy.com\/reprints\/>Reprints<\/a> | Share: &nbsp;<br \/>\n<a href=\"http:\/\/twitter.com\/home?status=RT%20@Xconomy%20Seattle%20Genetics%20Gets%20Roche%20Cash%20http:\/\/xconomy.com\/?p=66305\"  rel=\"nofollow\"><img decoding=\"async\" src=\"http:\/\/www.xconomy.com\/wordpress\/wp-content\/themes\/xconomy\/images\/twitter.gif\" alt=\"Retweet\"\/><\/a><br \/>\n&nbsp;<a href=\"http:\/\/www.facebook.com\/sharer.php?u=http:\/\/www.xconomy.com\/seattle\/2010\/03\/03\/seattle-genetics-gets-roche-cash\/&#038;t=Seattle%20Genetics%20Gets%20Roche%20Cash\"  rel=\"nofollow\"><img decoding=\"async\" src=\"http:\/\/www.xconomy.com\/wordpress\/wp-content\/themes\/xconomy\/images\/facebook.gif\" alt=\"Facebook\"\/><\/a><br \/>\n&nbsp;<a href=http:\/\/www.xconomy.com\/seattle\/2010\/03\/03\/seattle-genetics-gets-roche-cash\/email\/  rel=\"nofollow\"><img decoding=\"async\" src=\"http:\/\/www.xconomy.com\/wordpress\/wp-content\/themes\/xconomy\/images\/email.gif\" alt=\"Email\"\/><\/a><br \/>\n&nbsp;<a href=\"http:\/\/sharethis.com\/item?publisher=bfda184d-6684-4f7a-a23f-ca4ed4db9287&amp;title=Seattle+Genetics+Gets+Roche+Cash&amp;url=http%3A%2F%2Fwww.xconomy.com%2Fseattle%2F2010%2F03%2F03%2Fseattle-genetics-gets-roche-cash%2F\"><img decoding=\"async\" src=\"http:\/\/www.xconomy.com\/wordpress\/wp-content\/themes\/xconomy\/images\/share.gif\" alt=\"Share\"\/><\/a>\n<\/div>\n<p>\t     \t\t<br clear=\"both\" style=\"clear: both;\"\/><br \/>\n<br clear=\"both\" style=\"clear: both;\"\/><br \/>\n<a href=\"http:\/\/ads.pheedo.com\/click.phdo?s=8e4230d5e28ee7319d227ef90f53fd2d&#038;p=1\"><img decoding=\"async\" alt=\"\" style=\"border: 0;\" border=\"0\" src=\"http:\/\/ads.pheedo.com\/img.phdo?s=8e4230d5e28ee7319d227ef90f53fd2d&#038;p=1\"\/><\/a><br \/>\n<img loading=\"lazy\" decoding=\"async\" alt=\"\" height=\"0\" width=\"0\" border=\"0\" style=\"display:none\" src=\"http:\/\/a.rfihub.com\/eus.gif?eui=2218\"\/><\/p>\n<p><a href=\"http:\/\/feedads.g.doubleclick.net\/~a\/v26MnpTEnm_kjR3D88ZiiRuwH2o\/0\/da\"><img decoding=\"async\" src=\"http:\/\/feedads.g.doubleclick.net\/~a\/v26MnpTEnm_kjR3D88ZiiRuwH2o\/0\/di\" border=\"0\" ismap=\"true\"><\/img><\/a><br \/>\n<a href=\"http:\/\/feedads.g.doubleclick.net\/~a\/v26MnpTEnm_kjR3D88ZiiRuwH2o\/1\/da\"><img decoding=\"async\" src=\"http:\/\/feedads.g.doubleclick.net\/~a\/v26MnpTEnm_kjR3D88ZiiRuwH2o\/1\/di\" border=\"0\" ismap=\"true\"><\/img><\/a><\/p>\n<p><img loading=\"lazy\" decoding=\"async\" src=\"http:\/\/feeds.feedburner.com\/~r\/Xconomy_Full\/~4\/fqTzvZPchdI\" height=\"1\" width=\"1\"\/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Biotech, deals, cancer Luke Timmerman wrote: Seattle Genetics said today it has received an undisclosed milestone payment from Genentech, a wholly owned unit of Switzerland-based Roche. Seattle Genetics (NASDAQ: SGEN) is getting the payment because Genentech has filed an application with the FDA to begin clinical trials of an antibody for cancer that uses Seattle [&hellip;]<\/p>\n","protected":false},"author":1192,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[7],"tags":[],"class_list":["post-383623","post","type-post","status-publish","format-standard","hentry","category-news"],"_links":{"self":[{"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/posts\/383623","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/users\/1192"}],"replies":[{"embeddable":true,"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/comments?post=383623"}],"version-history":[{"count":0,"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/posts\/383623\/revisions"}],"wp:attachment":[{"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/media?parent=383623"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/categories?post=383623"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/tags?post=383623"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}